{"entity":{"id":"paper-alina-n-engl-j-med-2024","kind":"paper","name":"Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer","aka":[],"tldr":"Published report from the ALINA trial registered as NCT03456076, in New England Journal of Medicine (2024), chosen as the most cited paper whose own text cites the registry id.","summary":"Background: Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK -positive NSCLC are lacking.\n\nMethods: We conducted a global, phase 3, open-label, randomized trial in which patients with completely resected, ALK -positive NSCLC of stage IB (tumors ≥4 cm), II, or IIIA (as classified according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer and Union for International Cancer Control) were randomly assigned in a 1:1 ratio to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was disease-free survival, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat population. Other end points included central nervous system (CNS) disease-free survival, overall survival, and safety.\n\nResults: In total, 257 patients were randomly assigned to receive alectinib (130 patients) or chemotherapy (127 patients). The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001) and 93.6% and 63.7%, respectively, in the intention-to-treat population (hazard ratio, 0.24; 95% CI, 0.13 to 0.43; P<0.001). Alectinib was associated with a clinically meaningful benefit with respect to CNS disease-free survival as compared with chemotherapy (hazard ratio for CNS disease recurrence or death, 0.22; 95% CI, 0.08 to 0.58). Data for overall survival were immature. No unexpected safety findings were observed.\n\nConclusions: Among patients with resected ALK -positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.).\n\nIndexed on Europe PMC as PubMed record 38598794 (DOI 10.1056/nejmoa2310532). Its abstract cites the registry id NCT03456076, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"N Engl J Med 2024","url":"https://doi.org/10.1056/nejmoa2310532"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38598794/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/38598794"},{"label":"ClinicalTrials.gov NCT03456076","url":"https://clinicaltrials.gov/study/NCT03456076"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["alina"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/nejmoa2310532","pmid":"38598794","authors":"Wu YL, Dziadziuszko R, Ahn JS, et al.","paperType":"rct","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT03456076 with the most citations, so it is the natural first reading for anyone following the ALINA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-alina-n-engl-j-med-2024/","neighbours":{"trial":[{"id":"alina","kind":"trial","name":"ALINA","route":"/trials/alina/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}